Filing Details

Accession Number:
0001628280-25-001207
Form Type:
4
Zero Holdings:
No
Publication Time:
2025-01-10 18:45:36
Reporting Period:
2025-01-07
Accepted Time:
2025-01-10 18:45:36
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1104506 Insmed Inc INSM Pharmaceutical Preparations (2834) 541972729
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1796960 M.d. Martina Flammer 700 Us Highway 202/206
Bridgewater NJ 08807
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2025-01-07 3,344 $65.91 102,766 No 4 S Direct
Common Stock Disposition 2025-01-08 1,702 $66.16 101,064 No 4 S Direct
Common Stock Acquisiton 2025-01-08 6,657 $0.00 107,721 No 4 A Direct
Common Stock Disposition 2025-01-10 1,371 $63.73 106,350 No 4 S Direct
Common Stock Disposition 2025-01-10 4,801 $63.62 101,549 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 A Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Acquisiton 2025-01-08 31,930 $0.00 31,930 $65.72
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
31,930 2035-01-08 No 4 A Direct
Footnotes
  1. Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs) and to cover related broker fees.
  2. This is the weighted average sales price representing 3,344 shares sold at prices ranging from $65.57 to $65.99 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
  3. Due to a clerical error related to the reporting of shares previously withheld by the Company to satisfy tax obligations upon the vesting of RSUs, this number was previously overstated by 24 shares. This value reflects the adjustment, decreasing the amount beneficially owned by 24 shares.
  4. Represents RSUs, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested.
  5. Each RSU was granted on January 8, 2025 for no consideration.
  6. This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
  7. These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested.